New Review Flunks Most States in Tobacco Prevention Funding

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-Only 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association.

WASHINGTON—Only 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association. Only 6 of the 17—Arizona, Indiana, Maine, Massachusetts, Minnesota, and Mississippi—have met or exceeded the minimum spending recommended by the CDC—20% to 25%.

Articles in this issue
First Racial-Ethnic Breast and Cervical Cancer Screening Data
Mitotic Activity Index IDs High-Risk Node-Negative Breast Cancer
Programs Help Women/Physicians Decide on Adjuvant Therapy for Breast Cancer
No Recurrence in 971 Breast Cancer Patients With Negative SLNs Sentinel Lymph Node Biopsy
Disclosure Issues in Cancer Gene Testing Worry Doctors
Functional Assessment of Geriatric Cancer Patients Needed
Mobile Mammography Programs Are Struggling to Survive
Ellence Research Fund Names 11 Grant Recipients
Hyperfractionated RT Ups Pharynx Cancer Survival
Internet Creates Virtual Radiology Department
Dioxin TCDD Finally Listed as ‘Known’ Human Carcinogen
Fish Oil Concentrate Increases Doxorubicin Efficacy in Animals
RT Plus Chemo Ups Bladder Cancer Survival
Ductal Lavage Provides Early Detection of Atypical Cells
Study Clarifies When to Start HIV Therapy
Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Bill Seeks to Require Reporting of Extravasated Tissue in Radiology
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Overview and Presentation
Epithelioid Sarcoma: Overview and Presentation
4 experts in this video
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
2 experts in this video
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
2 experts in this video
Evaluating Chemotherapy-Free vs Chemotherapy-Containing Combos in First-Line EGFR-Mutated NSCLC: Pros and Cons
4 experts in this video
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Outlining Ongoing Clinical Developments in Treatment for Rare Lymphomas
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Addressing Racial Disparities, Social Barriers to Breast Cancer Care
Related Content
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Tim Cortese
April 18th 2025
Article

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.